Our team of medical supply experts combines AI-powered procurement with personalized service. Get custom solutions, volume pricing, and 24/7 support for your healthcare organization.
24/7 Availability
Round-the-clock support
Fast Response
Average 2hr reply time
Expert Team
Healthcare specialists
Free Quotes
No obligation pricing

SKU: LAC2232126
Product Description Cook Medical G44015 – TRAY, SPECTRUM TRIPLE LUMEN, EACH Cook Spectrum Central Venous Catheter Tray Double Lumen – Minocycline/Rifampin Impregnated To combat CRBSIs, we impregnate o.
Enter your ZIP code to see delivery options and costs.


To combat CRBSIs, we impregnate our polyurethane catheters with the clinically proven combination of minocycline and rifampin. More than 21 peer-reviewed articles and meta-analyses recognize Spectrum as superior — its evidence of protection no other process or technology can match. Furthermore, over 10 years of clinical use and a study of more than 500,000 catheter days show no evidence of bacterial resistance.1 Cook Spectrum catheters give your patients the best protection possible against CRBSI and may also provide significant economic benefits for your hospital.
Designed for treatment of critically ill patients and suggested for:
The activity of the antimcrobial agents, minocycline and rifampin, is localized at the internal and external catheter surface and is not intended for treatment of systemic infections. The device is a short-term use catheter.
| Order Number | Reference Part Number | Catheter Fr/Equivalent gage |
Catheter Length (cm) |
Wire Guide Diam/Fits Needle (inch/gage) |
Suture Needle Shape | Power-Injectable |
| G44015 | C-UTLMY-501J-RSC-ABRM-HC-FST | 5.0/16 | 12 | 0.025/19 | Straight | – |
![]() |
The Right Combination Minocycline+rifampin is the most rigorously studied and synergistic combination of antibiotics available on a catheter for reducing CRBSIs through two distinct mechanisms of action. Unlike most antibiotics, this combination has the ability to penetrate the biofilm that forms on all indwelling catheters. Unmatched EvidenceTwo decades of evidence, including more than 21 peer-reviewed studies and four meta-analyses, confirm minocycline+rifampin catheters are the most effective tool available to provide broad-spectrum protection against grampositive, gram-negative and fungal infections3,4 in both short- and long-term use. Its evidence of protection no other process or technology can match. No Eviden ce of ResistanceMore than 10 years of clinical use has shown no evidence that M+R catheters lead to bacterial resistance, and a seven-year study of over 500,000 catheter days confirms these results.1 A separate study indicates that a facility using M+R catheters may have shown a decrease in vancomycin usage. Worth SwitchingIn a challenging clinical environment, a hospital that switches to M+R catheters may expect to see a decrease in CRBSI rates, attributable mortality and CRBSI-related costs. Even high-performing hospitals can switch to Spectrum to drive incremental improvement in CRBSI rates and may still achieve substantial reductions in mortality and expenses. |
| Item Number | French Size | Length | Access Site |
|
G44015 |
5.0 |
12cm |
Right subclavian vein; for patients weighing 10-40 kilograms |
| French Size | Lumens | Equivalent Gage | Minimum Lumen Volume |
| 5.0 | #1 #2 #3 |
18 23 23 |
0.3cc 0.2cc 0.2cc |
Minocycline+rifampin is proven to be the most synergistic combination of antibiotics in reducing infections through two distinct pathways, and has the ability to penetrate the biofi lm that forms on all indwelling catheters.

Coated catheters [that can maintain an in vitro zone of inhibition] of = 15 mm were highly predictive of in vivo effi cacy.
In vitro studies show that our M+R catheters maintain an effective zone of inhibition for up to 21 days – longer than any other catheters. Over two decades of evidence, including more than 21 peer-reviewed studies and meta-analyses, prove M+Rs ability to prevent bloodstream infections.

More than 10 years of clinical use has shown no evidence that M+R catheters lead to bacterial resistance, and a seven year study of over 500,000 catheter days confirms these results.9 Data indicate that facilities using M+R catheters have a decreased need for systemic antibiotic use.

M/R CVC use is not associated with long term increased staphylococcal resistance to tetracyclines and rifampin; however, it represents a crucial strategy to significantly decrease CRBSI in critically ill cancer patients.
Supplied sterilized by ethylene oxide gas in peel-open packages. Intended for one-time use. Sterile if package is unopened or undamaged. Do not use the product if there is doubt as to whether the product is sterile. Store in a dark, dry, cool place. Avoid extended exposure to light. Upon removal from package, inspect the product to ensure no damage has occurred.